In this analysis, we extend our in-trial findings by including up to 6 additional years of follow-up per participant, to further ascertain how variability in BP across multiple annual study visits impacts the long-term risk of incident dementia and cognitive decline between the sexes, as well as how ApoE ɛ4 carrier status affects these risks. This evidence concerns the gene APOE and dementia.